Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | ABL2 | P42684 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 5/20 | 0.45 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | TEC | P42680 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16321782 | 1.00 | SRC (0.49) | SRCEGFRABL1ABL2BTK | |
| SCHEMBL15145742 | 0.94 | SRC (0.55) | SRCEGFRABL1ABL2HCAR1 | |
| SCHEMBL15156055 | 0.94 | SRC (0.55) | SRCEGFRABL1ABL2HCAR1 | |
| SCHEMBL14798023 | 0.91 | SRC (0.48) | SRCEGFRABL1ABL2PIK3CD | |
| SCHEMBL31626196 | 0.91 | SRC (0.48) | SRCEGFRABL1ABL2PIK3CD | |
| SCHEMBL28881338 | 0.88 | SRC (0.50) | SRCEGFRABL1ABL2HCAR1 | |
| SCHEMBL30760868 | 0.86 | SRC (0.47) | SRCEGFRABL1ABL2PIK3CD | |
| SCHEMBL30760919 | 0.86 | SRC (0.47) | SRCEGFRABL1ABL2PIK3CD | |
| SCHEMBL30760914 | 0.86 | SRC (0.47) | SRCEGFRABL1ABL2PIK3CD | |
| SCHEMBL30760832 | 0.86 | SRC (0.47) | SRCEGFRABL1ABL2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643716-B1 | HETEROARYL COMPOUND HAVING PHARMACEUTICAL ACTIVITY | SHANGHAI DUDE MEDICAL TECH CO LTD (CN) | 2022-05-04 | — | — | EP | disclosed |
| CN-109111446-B | Heteroaryl compound with pharmaceutical activity | 上海度德医药科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3643716-A1 | HETEROARYL COMPOUND HAVING PHARMACEUTICAL ACTIVITY | Shanghai Dude Medical Technology Co., Ltd (CN) | 2020-04-29 | — | — | EP | disclosed |
| US-20200123156-A1 | HETEROARYL COMPOUND HAVING DRUG ACTIVITY | SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTD | 2020-04-23 | — | — | US | disclosed |
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-9469642-B2 | Purinone compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-10-18 | — | — | US | disclosed |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123156-A1 | HETEROARYL COMPOUND HAVING DRUG ACTIVITY | BTK, LYN, LCK | SRC 7/4885EGFR 747/4885ABL1 5/4885 |
| US-20160368924-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | SRC 19/4885EGFR 1723/4885ABL1 18/4885 |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | SRC 19/4885EGFR 1723/4885ABL1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.